Table 6.
Clinical trials of PVSRIPO
| Therapeutic agent | Cancer type | Phase, study type | Mode of therapy | Purpose of the study | Status | Clinical trial number |
|---|---|---|---|---|---|---|
| PVSRIPO | Recurrent glioblastoma | Phase 1, open-label, sequential assignment | Intra-tumoral infusion | Dose and safety determination | Active, not recruiting | NCT01491893 |
| PVSRIPO | Malignant glioma | Phase 2, open-label, single-group study | Intra-tumoral administration by convection-enhanced delivery (CED) | Single dose efficacy assessment | Recruiting | NCT02986178 |
| PVSRIPO | Recurrent malignant glioma | Phase1, open-label, single-group assignment | Intra-tumoral delivery by CED | Safety and dose determination | Recruiting | NCT03043391 |